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Circulating levels of insulin and glucagon reflect the
nutritional state of animals and elicit regulatory
responses in the liver that maintain glucose and lipid
homeostasis. The transcription factor Foxa2 acti-
vates lipid metabolism and ketogenesis during fast-
ing and is inhibited via insulin-PI3K-Akt signaling-
mediated phosphorylation at Thr156 and nuclear
exclusion. Here we show that, in addition, Foxa2 is
acetylated at the conserved residue Lys259 following
inhibition of histone deacetylases (HDACs) class I–III
and the cofactors p300 and SirT1 are involved in
Foxa2 acetylation and deacetylation, respectively.
Physiologically, fasting states and glucagon stimula-
tion are sufficient to induce Foxa2 acetylation. Intro-
duction of the acetylation-mimicking (K259Q) or
-deficient (K259R) mutations promotes or inhibits
Foxa2 activity, respectively, and adenoviral expres-
sion of Foxa2-K259Q augments expression of genes
involved in fatty acid oxidation and ketogenesis. Our
study reveals a molecular mechanism by which
glucagon signaling activates a fasting response
through acetylation of Foxa2.
INTRODUCTION
Mammals have evolved complex mechanisms to maintain
energy homeostasis during periods of nutritional abundance
and starvation. The nutritional state of an organism is reflected
by the circulating levels of the two pancreatic hormones insulin
and glucagon, which elicit regulatory responses in the peripheral
tissues as a means of maintaining glucose and lipid homeo-
stasis. In particular, the liver acts as a ‘‘metabolic integrator,’’
by regulating glycogen degradation, gluconeogenesis, fatty
acid oxidation, and ketogenesis, thereby maintaining normogly-
cemia and ensuring constant energy supply to glucose-depen-
dent tissues such as the brain.
Following food intake, plasma insulin levels rise and suppress
hepatic glucose production, b-oxidation, and ketogenesis and436 Cell Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc.instruct the liver to convert glucose to glycogen for storage—
a process regulated by the insulin-sensitive enzyme glycogen
synthase kinase-3—and promote triglyceride (TG) synthesis as
well as de novo lipogenesis (Kahn et al., 2006). Many metabolic
responses are elicited by changes in plasma insulin levels that
are mediated by the insulin/PI3K/Akt signaling cascade. Down-
stream targets of the Akt kinases are the tuberous sclerosis 1
(Tsc1)-Tsc2 complex, glycogen synthase kinase 3 (GSK3), and
several members of the forkhead box transcription factors (Salt-
iel and Kahn, 2001), such as Foxo1, which plays a central role in
hepatic glucose metabolism (Lin and Accili, 2011), and Foxa2,
a key regulator of hepatic lipid metabolism. The forkhead
member Foxa2, which is transcriptionally active in the fasted
state and induces expression of enzymes involved in fatty acid
oxidation, ketogenesis, and VLDL secretion and bile acid metab-
olism (Wolfrum et al., 2004; Wolfrum and Stoffel, 2006; Bochkis
et al., 2008), is regulated via insulin/PI3K/Akt-mediated phos-
phorylation at a single conserved threonine (Thr156) residue
(Wolfrum et al., 2003). This phosphorylation event attenuates
Foxa2 activity and triggers nuclear export in a CRM1-dependent
manner (Wolfrum et al., 2003, 2004; Howell and Stoffel, 2009;
Pandey et al., 2009; Banerjee et al., 2010). Interestingly, insulin
inhibits the transcriptional activity of Foxa2 in the liver not only
during feeding, but also in hyperinsulinemic ob/ob or db/db
mice and in animals with diet-induced obesity. Expression of
constitutively active Foxa2-T156A in diabetic mice normalizes
plasma glucose levels, decreases hepatic triglyceride content,
increases insulin sensitivity, and elevates hepatic lipid metabo-
lism by activating the expression of genes encoding enzymes
involved in mitochondrial b-oxidation and ketogenesis, such as
CPT1a, MCAD, VLCAD, or HMGCS (Wolfrum et al., 2004; Wolf-
rum and Stoffel, 2006).
During starvation or hypoglycemia, high glucagon concentra-
tions induce glycogen breakdown and gluconeogenesis in the
liver in order to release glucose into the circulation (Habegger
et al., 2010). Glucagon also stimulates hepatic mitochondrial
b-oxidation to supply energy for glucose production and conver-
sion of fatty acids into ketone bodies, which can provide up to
two-thirds of the energy for the brain in periods of glucose
shortage. At the molecular level, binding of glucagon to its
receptor causes activation of a heterotrimeric, stimulatory G
protein (GS), which subsequently leads to interaction and stimu-
lation of adenylate cyclase and elevation of cAMP levels and
AC
F G
D E
B Figure 1. Lys259 Is Acetylated in Foxa2
(A) Hepa1-6 cells were infected with recombinant
adenovirus expressing HA-tagged Foxa2 prior to
overnight serum starvation and treated with 5 mM
Nam and 2 mM TsA for 2 hr. Foxa2-HA was
immunoprecipitated using an anti-HA antibody,
and acetylated Foxa2 was detected using a global
acetylated lysine antibody.
(B) Samples under (A) were further processed for
MS analysis. Tandem MS analyses of acetylated
Foxa2 are shown that identify Lys259 (K* corre-
sponds to the acetylated lysine).
(C) Absolute intensities of the peptides containing
Ac-Lys259 (black) and Ac-Lys275 (gray) obtained
by MS analysis after addition of the inhibitor TsA/
Nam to Hepa1-6 cells.
(D) Hepa1-6 cells were infected with the indi-
cated recombinant adenovirus expressing HA-
tagged Foxa2 and treated as indicated. Immu-
noblots of whole lysis and precipitates were
probed with antibodies against HA and acety-
lated lysine.
(E) Hepa1-6 and HepG2 were infected with the
indicated recombinant adenovirus expressing
HA-tagged Foxa2 and treated with TsA/Nam for
2 hr. Immunoblots of precipitates were probed
with antibodies against HA and acetylated Foxa2
Lys259.
(F) Hepa1-6 cells were treated with TsA/Nam for
the indicated time, and acetylated Foxa2 Lys259
was detected by western analysis.
(G) Hepa1-6 cells, cultured in full medium, were treated with TsA/Nam for 2 hr and subsequently washed and incubated in full medium lacking
TsA/Nam for the indicated time. Acetylated Foxa2 Lys259 was detected by western analysis. Ctrl: non-inhibitor-treated cells.
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regulated transcription coactivator 2 (CRTC2; TORC2) and
protein kinase A (PKA) (Habegger et al., 2010). A target of active
PKA is CREB, which upon phosphorylation translocates into the
nucleus and promotes expression of gluconeogenic genes, such
as pyruvate carboxylase, PEPCK1, or G6PC (Altarejos and
Montminy, 2011) or salt-inducible kinase 2 (SIK2), an inhibitor
of CRTC2 (Koo et al., 2005). CRTC2 activity is also regulated
by CBP/p300-mediated acetylation, and p300 activity is sup-
pressed by phosphorylation via SIK2 (Liu et al., 2008).
In this study, we tested the hypothesis that PTMs other than
phosphorylation regulate the activity of Foxa2. Our unbiased
analysis of posttranslational modifications of Foxa2 revealed
an evolutionarily conserved and regulated acetylation site that
modulates the transcriptional activity and hepatic lipid metabo-
lism in response to fasting and glucagon stimulation.
RESULTS
Foxa2 Is Acetylated at Lys259 and Lys275
To investigate whether Foxa2 is modified by acetylation, we ex-
pressed recombinant HA-tagged wild-type Foxa2 in the mouse
liver cell line Hepa1-6 using an adenovirus and treated the cells
with an histone deacetylase (HDAC) inhibitor cocktail containing
trichostatin A (TsA) and nicotinamide (Nam). After immunopre-
cipitation of Foxa2, we could detect acetylated Foxa2 in the
presence of the inhibitor cocktail using an anti-acetyl-lysine
antibody (Figure 1A). Tandem mass spectrometry (MS) analysis
of affinity-purified HA-Foxa2, expressed in liver cells in the pres-Ceence of HDAC inhibitors, identified two specific acetylation
sites, namely Lys259 and Lys275 (Figures 1B and S1A). We
found both sites acetylated upon HDAC inhibition (Figure 1C).
To confirm these results, we generated recombinant adenovi-
ruses expressing acetylation-deficient Foxa2 by mutating
Lys259 and Lys275 to arginine (K259R and K275R, respec-
tively). When cells were infected with the single mutants
K259R or K275R, acetylated lysine was still detectable, whereas
double mutant Foxa2 (K259R-K275R) profoundly diminished
the effect of the inhibitor cocktail on Foxa2 acetyl-lysine (Fig-
ure 1D). These results indicate that Lys259 and Lys275 are
the two principal lysine residues acetylated in the presence of
the HDAC inhibitors in the liver cell line Hepa1-6. We were
also able to detect acetylation of Foxa2 Lys259, but not
Foxa2 Lys275, in the human liver cell line HepG2 by MS analysis
(Figure S1B).
Since Foxa2 Lys259 is highly conserved in vertebrates as well
as within the FoxA subfamily (Figure S1C) and is localized at the
junction of the nuclear localization sequence (NLS) and the DNA
binding domain (Howell and Stoffel, 2009), we decided to study
the biological function of acetyl-Lys259. We generated a specific
anti-Foxa2-Ac-Lys259 antibody, which recognizes acetylated
Foxa2 in mouse Hepa1-6 cells, as well as in human HepG2 cells
(Figure 1E). Accumulation of acetyl-Lys259 can be detected
within 2 hr of HDAC inhibitor treatment in whole-cell lysates
and immunoprecipitated Foxa2 (Figure 1F), and Lys259 is
rapidly deacetylated after HDAC inhibitor removal (Figure 1G),
with acetyl-Lys259 being detectable 5 min after medium
replacement and markedly diminished after 15 min. Similarll Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc. 437
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Figure 2. Foxa2 Lys259 Is Acetylated by
HAT p300 and Deacetylated by HDACs of
Class I/II and Sirt1
(A) Primary hepatocytes from C57BL/6 mice were
transfected with expression vectors containing
Foxa2 in combination with the indicated KAT
constructs. Forty-eight hours posttransfection,
cells were treated with 2 mM TsA and 5 mM Nam
for 2 hr, and Foxa2-HA were immunoprecipitated
using anti-HA antibodies. Acetylated Lys259 in
Foxa2 were detected using an acetylated Foxa2
Lys259 specific antibody.
(B and C) Hepa1-6 were transfected with expres-
sion vectors containing Foxa2 in combination with
siRNAs against the indicated HDACs. Forty-eight
hours posttransfection, cells were treated with
2 mM TsA or 5 mM Nam for 2 hr, and acetylated
Lys259 in Foxa2 were assessed by western anal-
ysis. siRNA sequences are shown in Table S1.
(D) Hepa1-6 cells were infected with recombinant
adenovirus expressing HA-tagged Foxa2 con-
structs as indicated and treated with TsA/Nam for
2 hr. Immunoblots of whole-cell lysis and immu-
noprecipitates (IP-HA) were probed for endoge-
nous Sirt1 and HA-tagged Foxa2.
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medium without FBS (data not shown). These results indicate
that acetylation at Lys259 in Foxa2 is a highly dynamic and
reversible process.
Sirt1 and p300 Regulate Acetylation of Foxa2
Acetylation is regulated by two groups of enzymes, lysine-ace-
tyltransferases (KATs) and HDACs. KATs are divided into two
main categories, KAT A and KAT B, which can be further classi-
fied into subclasses. CBP/p300, PCAF, GCN5, Tip60, and SRC1
are representative members. To identify the KAT that acetylates
Foxa2 at Lys259, we cotransfected HA-tagged Foxa2 with at
least one KAT of each subclass. After 48 hr cells were treated
with TsA/Nam and levels of acetyl-Lys259 were measured
(Figures 2A, S2A, and S2B). Overexpression of p300 alone is
sufficient to detect acetyl-Lys259, which can be further
increased with HDAC inhibitor treatment. The constitutively
active KAT p300D33 enhanced the acetyl-Lys259 signal
compared to wild-type p300 on HA-tagged Foxa2 and also re-
sulted in acetylation of endogenous Foxa2 (Figure S2C). Knock-438 Cell Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc.down of p300 by RNAi decreased the
TsA/Nam-induced acteyl-Lys259 signal
(Figure S2D). Consistent with this, phar-
macological inhibition of p300 markedly
reduced the induction of acetyl-Lys259
by TsA/Nam (Figure S2E). These data
demonstrate that p300 is responsible for
acetylating Foxa2 Lys259.
We next used a genetic and a pharma-
cological approach to identify the HDACs
responsible for deacetylating Foxa2
Lys259. Cells were transfected with
siRNAs targeting HDACs of class I/II or
class III (sirtuins) and 48 hr later treatedfor 2 hr with the class III inhibitor Nam or with the class I/II inhib-
itor TsA, respectively (Figures 2B, 2C, and S2F). Knockdown of
HDACs of class I/II in the presence of Nam did not result in
increased acetyl-Lys259 levels, whereas knockdown of Sirt1 in
combination with TsA led to increased acetylation of Foxa2
Lys259. In the complementary pharmacological approach, inhi-
bition of a single class of HDAC using TsA for class I/II or Nam for
class III did not enrich for acetyl-Lys259 (Figure S2G). Consistent
with the result from the siRNA-mediated knockdown of HDACs,
only inhibition of class I/II HDACs in combination with class III
HDAC inhibitor TsA or the specific Sirt1 inhibitor Ex527 led to
increased acetylation of Foxa2 Lys259. To confirm the role of
Sirt1 as a Foxa2 deacetylase, we infected primary hepatocytes
from wild-type or liver-specific Sirt1 knockout mice (Sirt1fl/fl 3
AlbCre) mice with recombinant adenovirus expressing HA-
tagged Foxa2 prior to overnight starvation (Figure S2H). Acetyla-
tion of Foxa2 Lys259 was detected in primary hepatocytes in the
absence of Sirt1.
In order to explore whether Foxa2 physically interacts with
p300 and Sirt1, Hepa1-6 cells were infected with adenovirus
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Figure 3. Hepatic Foxa2 Lys259 Is Acety-
lated in Response to Glucagon
(A) Primary hepatocytes from C57BL/6 mice were
infected with recombinant adenovirus expressing
HA-tagged Foxa2 prior to overnight fasting and
then treated with glucagon (0.5 mg/ml) or forskolin
(10 mM) for 30 min. Acetylated Foxa2 Lys259 was
detected in Foxa2-HA immunoprecipitates.
(B) C57BL/6 mice were injected with recombinant
adenovirus expressing HA-tagged Foxa2 and
analyzed in ad libitum fed state or after a 14 or 24 hr
fast. Acetylated Foxa2 Lys259 in the livers of fas-
ted animals was detected in Foxa2-HA immuno-
precipitates.
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antibodies showed that Foxa2 was able to pull down endoge-
nous Sirt1, independent of whether the cells were treated
with TsA/Nam or not (Figure 2D). We also tested if Lys259
acetylation-mimicking (K259Q) or acetylation-deficient mutants
(K259R) interact with Sirt1 and p300 by expressing Foxa2
K259Q or K259R in Hepa1-6 cells. The K259Q and the K259R
mutants were able to coimmunoprecipitate endogenous Sirt1
and endogenous p300 (Figure S2I). These experiments show
that Foxa2 can interact with Sirt1 and p300.
Foxa2 K259 Is Acetylated upon Fasting or Glucagon
Stimulation
To identify physiological triggers for Foxa2-Lys259 acetylation,
we isolated primary hepatocytes from wild-type mice; chal-
lenged them with several stimuli including metformin, AICAR, ra-
pamycin, tunicamycin, cisplatin, etoposide, UV light, H2O2, heat
shock, palmitate, insulin, glucagon, and forskolin; and analyzed
the cell extracts for acetylated Lys259 (data not shown). Only
upon stimulation with the pancreatic hormone glucagon could
we detect an increase in the levels of acetylated Lys259, inde-
pendent of HDAC inhibition (Figure 3A). In addition, forskolin,
a commonly used drug to raise levels of cyclic AMP (cAMP),
which are also raised in response to glucagon stimulation, was
also able to increase Foxa2 Lys259 acetylation in primary hepa-
tocytes. Downstream targets of the glucagon signaling pathway
such as P-Creb were also activated in response to glucagon or
forskolin treatment. We also detected a reduction of the inhibi-
tory Ser89 phosporyaltion of p300 (Liu et al., 2008) in the
glucagon-treated samples. Since glucagon levels are increased
in the fasted state, opposing the actions of insulin, we sought to
verify whether Foxa2 Lys259 acetylation was also regulated
in vivo in response to fasting. We expressed HA-tagged wild-
type Foxa2 in livers of lean mice using recombinant adenovirus
and starved these animals. Whereas we did not detect Lys259
acetylation in ad libitum fed mice, acetylation levels increasedCell Metabolism 17, 436–4after short starvation and even more after
a long starvation period (Figure 3B). In
agreement with the in vitro results, levels
of Ser89 phosporyaltion of p300 were
also reduced in the starved animals, and
p53 Lys379 acetylation, a direct target
of Sirt1, decreased with starvation. To
summarize, Foxa2 Lys259 acetylationwas increased upon glucagon stimulation in vitro and upon star-
vation in vivo.
Acetylation of Foxa2 Modulates Its Localization
and Activity
Foxa2 shuttles from the nucleus to the cytoplasm in response to
insulin signaling (Wolfrum et al., 2003). Since Lys259 resided at
the junction of the NLS, we investigatedwhether acetylation influ-
ences intracellular localization of Foxa2. Treatment of Hepa1-6
cells with TsA and Namblocked insulin-dependent nuclear exclu-
sion of endogenous Foxa2 without affecting insulin signaling
(Figures 4A and S3A). To further elucidate if Lys259 is responsible
for localizationofFoxa2 invivo,we injectedadenovirusexpressing
wild-type, K259Q, or K259R constructs or the nuclear and con-
stitutively active T156Amutant into wild-typemice. Both endoge-
nous and exogenous wild-type Foxa2were located in the nucleus
in all fasted animals (Figures 4B and 4C). As previously reported,
hepatic Foxa2 was excluded from the nucleus of ad libitum fed
animals,whereas the phosphorylation-deficientmutant T156A re-
mained nuclear. Interestingly, the acetyl-deficient K259R mutant
was mainly cytoplasmic in the fasted state, whereas the acetyl-
mimic K259Q mutant remained in the nucleus in the fed state.
Wepreviously reported that thephospho-deficientT156Aremains
nuclear even in the presence of insulin signaling and is tran-
scriptionally active. In order to investigate how the modifications
affect one another, we combined acetylation mutations with
T156A that inhibits Akt-mediated phosphorylation. Interestingly,
the double T156A-K259R mutant was localized mainly to the
cytosol, thereby behaving almost like the single K259R mutant.
In order to test if the nuclear localization of Foxa2 correlates
with increased transcriptional activity, we analyzed acetylation-
deficient and -mimic Foxa2 Lys259 mutants in livers of fed
wild-type mice that were injected with adenovirus expressing
the indicated Foxa2 mutants. The hepatic expression levels of
all HA-tagged mutants were similar (Figure 4D). Transcript
levels of known Foxa2 target genes encoding enzymes involved47, March 5, 2013 ª2013 Elsevier Inc. 439
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Figure 4. Acetylating Foxa2 Determines Its Localization and Activity
(A) Immunoblots showing cellular fractionation of Hepa1-6 cells, which have been serum-starved overnight and stimulated with 500 nM insulin for 15min after 2 hr
TsA/Nam treatment.
(legend continued on next page)
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Regulation of Foxa2 Activity by Glucagonin b-oxidation and ketone body formation were upregulated
in livers overexpressing K259Q, T156A, and T156A-K259Q
mutants compared to livers expressing wild-type Foxa2 or
K259R and T156A-K259R mutants (Figure 4E). These data indi-
cate that acetylation at Lys259 not only determines subcellular
localization but also regulates transcriptional activity of Foxa2.
To determine whether DNA binding is affected in the different
Foxa2 mutants, we performed chromatin immunoprecipitation
(ChIP) analyses of the MCAD promoter in fasted and insulin-
stimulated primary hepatocytes of C57BL/6 mice infected
with recombinant adenovirus expressing the indicated Foxa2
mutants (Figure 4F). Wild-type Foxa2 binding to Foxa2 sites in
the MCAD promoter was decreased by insulin stimulation, while
K259Q and T156A were bound to the promoter independent of
insulin stimulation. The fold enrichment of K259R at the MCAD
promoter was in all states comparable to the levels found in
insulin-stimulated wild-type Foxa2 samples.
We next investigated whether hepatic expression of the Foxa2
mutants that lack or mimic acetylation states has an impact on
liver metabolism and/or insulin tolerance in lean mice. Liver
triglyceride levels, mitochondrial b-oxidation, and ketogenesis
and plasma ketone body concentrations were similar in all
groups (Figures S3B–S3E), and insulin tolerance, determined
during an intraperitoneal insulin tolerance test, revealed no
significant differences in the integrated glucose area under the
curve (Figures S3F and S3G). These results indicate that tran-
sient overexpression of Foxa2 acetylation mutants does not
affect glucose and lipid metabolism in chow-fed mice and are
in agreement with earlier observations showing normal metabo-
lism following adenoviral overexpression of constitutively active
Foxa2-T156A in lean wild-type mice (Wolfrum et al., 2004).
Foxa2 K259 Is Constitutively Active in Hyperinsulinemic
ob/ob Mice
Endogenous Foxa2 is permanently inactivated in high-fat diet
and genetic obesemousemodels by nuclear exclusion (Wolfrum
et al., 2004; Silva et al., 2009) and therefore a good model to
study the physiological effect of mutant Foxa2 proteins. For
instance, we previously showed that Foxa2-T156A is able to
restore Foxa2 activity, whereas wild-type Foxa2 is constitutively
cytoplasmic and inactive in these hyperinsulinemic mice (Wolf-
rum et al., 2004). Using recombinant adenoviruses, we ex-
pressed wild-type Foxa2; single T156A, K259R, and K259Q;
and double T156A-K259R and T156A-K259Q mutants in livers
of ob/ob mice (Figure 5A). Nuclear and cytoplasmic extracts
from liver of these mice showed that wild-type Foxa2, K259R,
and T156A-K259R are constitutively cytoplasmic, whereas the
T156A, K259Q, and T156A-K259Q Foxa2 proteins remained in
the nucleus (Figure 5B). We next examined the activity of
Lys259 mutants in these mice by measuring Foxa2 target gene(B–E) C57BL/6 mice were injected with the indicated adenovirus expressing HA-
were analyzed by immunofluorescence microscopy (B) or cellular fractionation an
insulin 15 min prior to harvesting (B). Lamin B and Gapdh expression levels we
showing the expression levels of hepatic Foxa2-HA are shown (D). Transcript leve
with recombinant adenovirus expressing the indicated Foxa2mutants (E). The rela
are normalized to 36B4 expression levels. MCAD, medium-chain acyl-CoA dehyd
palmitoyltransferase 1a; HMGCS, HMG CoA synthase.
(F) ChIP analysis of the MCAD promoter in fasted and insulin-stimulated prim
expressing the indicated Foxa2 mutants. Values are the mean ± SD; *p < 0.05; n
Ceexpression using quantitative real-time PCR. Consistent with
previous findings from ad libitum fed C57BL/6 mice (Figure 4E),
mRNA levels of target genes encoding for enzymes involved in
mitochondrial b-oxidation and ketogenesis were not changed
in livers overexpressing Foxa2, K259R, and T156A-K259R but
were significantly upregulated in livers of T156A, K259Q, and
T156A-K259Q injected hyperinsulinemic mice (Figure 5C). To
further elucidate the physiological effect of the Lys259 mutants
in ob/ob mice, we monitored plasma insulin concentration
before and after adenoviral expression of Foxa2 mutants (Fig-
ure 5D). A significant decrease was observed in mice injected
with adenovirus expressing T156A, K259Q, and T156A-K259Q
Foxa2 mutants. This decrease correlated with increased levels
of phosphorylation of key phosphoproteins of the insulin-
signaling cascade in livers of mice injected with adenovirus ex-
pressing T156A and K259Q mutants (Figure 5E). Consistent
with the gene expression data, we also observed no changes
in ketone body production and fatty acid oxidation in isolated
mitochondria from ob/ob mice that were infected with adeno-
virus expressing Foxa2, K259R, and T156A-K259R mutants. In
contrast, mice injected with T156A, K259Q, and T156A-K259Q
showed significant increases in fatty acid metabolism (Figures
5F and 5G). In addition, liver triglyceride concentrations revealed
a similar trend, with decreases observed only in livers of mice ex-
pressing active T156A, K259Q, and T156A-K259Q (data not
shown). Taken together, these results indicate that Foxa2 acet-
ylation also increases the activity of Foxa2 in hyperinsulinemic,
insulin-resistant mice.
Foxa2-K259Q Improves Hepatic Metabolism
in db/db Mice
Obese db/dbmice on the BKS background develop an extreme
type 2 diabetes phenotype, with hyperglycemia, obesity,
hepatic steatosis, and (in the beginning) elevated plasma insulin
concentrations. We used this model to study the physiological
and metabolic consequences of expressing Foxa2 acetylation
mutants in the liver under extreme metabolic conditions. Adeno-
viral expression of T156A, K259Q, and T156A-K259Q mutants
results in significant improvement of the initial hyperglycemia
as soon as 2 days after injection (Figure 6A), without causing
any body weight loss (Figure 6B). This effect was not observed
in wild-type Foxa2-, K259R-, T156A-K259R-, GFP-, or PBS-
injected animals, although hepatic Foxa2-HA expression levels
were comparable between all Foxa2 mutants (Figure S4A). In
addition, in T156A, K259Q, and T156A-K259Q animals, plasma
insulin levels dropped more than 3-fold (Figure 6C), and insulin
sensitivity, determined during an intraperitoneal insulin toler-
ance test, was significantly increased (Figures 6D and S4B)
when compared to wild-type Foxa2-, PBS-, or GFP-injected
animals.tagged Foxa2. Livers of mice that were either fasted for 16 hr or fed ad libitum
d immunoblotting (C). Ad libitum fed mice were additionally treated with 1 U/kg
re used as the nuclear and cytosolic markers, respectively (C). Immunoblots
ls of Foxa2 target genes were measured in livers of fed C57BL/6mice injected
tive mRNA abundance of Foxa2 target genes was determined by qPCR. Values
rogenase; VLCAD, very-long-chain acyl-CoA dehydrogenase; CPT1a, carnitine
ary hepatocytes from C57BL/6 mice infected with recombinant adenovirus
= 4.
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Figure 5. Foxa2-K259Q Is Active in Livers of
Hyperinsulinemic ob/ob Mice
(A) Immunoblots showing the expression levels of
Foxa2-HA.
(B) Immunoblots showing cellular fractionation of
livers from ob/ob mice infected with adenovirus
expressing HA-tagged Foxa2 mutants. Lamin B
andGapdh expression levels were used as nuclear
and cytosolic markers, respectively.
(C–G) Transcript levels of Foxa2 target genes and
metabolic parameters were measured in ob/ob
mice injected with the indicated adenovirus.
Shown are mean mRNA levels of Foxa2 target
genes from liver (C), plasma insulin levels before
and after adenovirus injection (D), and key phos-
phoproteins of the insulin-signaling cascade that
were analyzed by western blotting (E). b-oxidation
(F) and ketone body production (G) by liver mito-
chondria from ob/ob animals wasmeasured by the
formation of 14CO2 and
14C-labeled acid-soluble
products, respectively, from 14C-palmitic acid.
Values are the mean ± SD; **p < 0.01; ***p < 0.001;
n = 5–6.
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Regulation of Foxa2 Activity by GlucagonHepatic steatosis, quantifiedas total triglyceridecontentor inoil
redOstainingson liver sections (Figures6Eand6F),wasmarkedly
reduced in animals after T156A, K259Q, and T156A-K259Q
expression. Consistent with these results, ketogenesis and mito-
chondrialb-oxidationwere increased in liversofmice injectedwith
Foxa2T156A,K259Q, or T156A-K259Q (Figures 6GandS4C).We
also found increased plasma ketone body concentrations inmice
expressing Foxa2 T156A, K259Q, or T156A-K259Q (Figure 6H),
while plasma triglyceride, nonesterified fatty acid (NEFA), and
cholesterol levels were not significantly altered after Foxa2
mutant expression (FiguresS4D–S4F). To summarize, expression
of Foxa2-T156A, K259Q, and T156A-K259Q mutants in the liver442 Cell Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc.of db/db mice improved hyperglycemia,
hepatic steatosis, and insulin sensitivity,
whereas wild-type Foxa2, K259R, and
T156A-K259R mutants had no effect on
these parameters.
DISCUSSION
Foxa2 has been shown to be a key regu-
lator of the transcriptional program of the
liver in response to fasting and feeding
(Wolfrum et al., 2004; Zhang et al.,
2005). Earlier studies showed that Foxa2
is inactivated upon feeding or increased
plasma insulin levels via insulin-PI3K-Akt
signaling-mediated phosphorylation at
Thr156 and nuclear exclusion (Wolfrum
et al., 2003).
We have now identified a regulatory
posttranslational modification (PTM) of
Foxa2, namely acetylation at Lys259,
catalyzed by the lysine acetyl transferase
p300. Computational analysis (http://ds9.
rockefeller.edu/basu/predmod.html) pre-dicted Lys275 acetylation, which we could also experimentally
confirm, but failed to identify Lys259 acetylation. Our subse-
quent studies focused on Lys259, since only this residue was
also acetylated in the human liver cell line HepG2. A recent
in silico study has also predicted several putative p300 acetyla-
tion sites on the homologous transcription factor Foxa1, among
them Foxa1 Lys270, which corresponds to Lys259 in Foxa2.
Acetylation assays with purified recombinant Foxa1 and p300
or the catalytic domain of p300 showed that Foxa1 can be acet-
ylated in vitro and that the DNA binding potential of in vitro acet-
ylated Foxa1 is diminished (Kohler and Cirillo, 2010). In contrast
to our study, Kohler and Cirillio focused on Foxa1, which, albeit
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Figure 6. Foxa2-K259Q Is Active in Livers of
Hyperinsulinemic db/db Mice
(A–H) Obese db/db (on a BKS background) mice
were injected with recombinant adenovirus ex-
pressing the indicated Foxa2 mutants. Blood
glucose levels (A), bodyweight (B), plasma insulin
(C), and plasma ketone body concentrations (D)
were measured before (day 0) and during the
study. (E) Total liver triglyceride content was
measured from 50 mg liver tissue. (F) Represen-
tative images of oil red O stainings of fixed liver
sections from animals treated with the indicated
adenovirus. (G) Insulin sensitivity was assayed
during an intraperitoneal insulin tolerance test
using 2 U/kg insulin. Areas under the curve (AUC)
quantifications for glucose of averaged individual
animals excluding the 15 min time point are
shown. (H) Ketone body production by liver mito-
chondria from fasted animals was measured by
the formation of 14C-labeleld acid-soluble prod-
ucts from 14C-oleic acid. Values ± SD; *p < 0.05;
**p < 0.01; ***p < 0.001; nR 4. In (A), (C), and (E),
values are the mean ± SEM; n = 6–17.
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Regulation of Foxa2 Activity by Glucagonhomologous to Foxa2, has different biological functions (Le Lay
and Kaestner, 2010), andmainly used in vitro systems with over-
expressed KATs, thereby forcing acetylation under nonphysio-
logical conditions. Furthermore, we could not detect acetylation
at any of the other predicted lysine residues in the winged helix
domain, although the sequences are well conserved between
Foxa1 and Foxa2 and were covered by our tandemMS analysis.
In our study, we could show that acetylation of Foxa2 Lys259 is
indeed catalyzed by p300 and demonstrate that both proteins
also physically interact. Supporting our findings, earlier studies
have demonstrated that Foxa2 and p300 are found inCell Metabolism 17, 436–4complexes (Rausa et al., 2003) and
have synergistic effects at promoter sites
(Liu et al., 2005; Qi et al., 2010). However,
these studies did not report acetylation of
Foxa2. Next, our results showed that de-
acetylation of Foxa2 is dependent on
several HDACs, since inhibition of class
I/II and III HDACs was necessary to
detect increased Foxa2 acetylation. It
has been reported that the 18 HDACs,
which can be subdivided in four classes,
show functional redundancy (Haberland
et al., 2009), for instance in deacetylating
lysine residues of NF-kB (Spange et al.,
2009). Knockdown of Sirt1, belonging to
HDAC class III and physically interacting
with Foxa2, in combination with class I/II
inhibition was sufficient to prevent Foxa2
deacetylation, proving an involvement of
Sirt1 to be the responsible HDAC class
III for Foxa2 in the regulation of Foxa2
acetylation. The class I/II HDACs respon-
sible for deacetylation of Foxa2 are
currently unknown. Their relative contri-
bution on Foxa2 acetylation and activityas well as their regulation by endogenous and external factors
will be important to study in the future.
Next we could demonstrate that glucagon promotes acetyla-
tion of Foxa2 Lys259. The notion that glucagon increases the
activity of Foxa2 is in agreement with the known role of the
pancreatic hormone in many metabolic pathways, besides its
function as a regulator of glucose homeostasis (Habegger
et al., 2010). It was shown that either prolonged fasting or
glucagon treatment stimulated the rate of hepatic fatty acid
oxidation and the expression of genes involved in b-oxidation,
such as CPT1a or MCAD, in wild-type but not in glucagon47, March 5, 2013 ª2013 Elsevier Inc. 443
Figure 7. Model for Regulation of Foxa2 Activity by Insulin and
Glucagon Signaling in Fed and Fasted States, Respectively
Schematic representation illustrating the regulation of Foxa2 and its target
genes in hepatic lipid metabolism and ketogenesis. After feeding, insulin
signaling leads to the inactivation of Foxa2 through phosphorylation of Thr156,
nuclear exclusion, thereby resulting in inhibition of Foxa2 target gene
expression and reduced hepatic lipid metabolism and gluconeogenesis.
During fasting, plasma insulin levels decrease and glucagon levels rise.
Glucagon signaling activates the adenylate cyclase (AC), leading to inhibition
of SIK2, a negative regulator of p300 activity. Acetylation of Foxa2 Lys259
by p300 increases its transcriptional activity. Sirt1 can inactivate Foxa2 by
deacetylation and can thereby fine-tune the activity of Foxa2.
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Regulation of Foxa2 Activity by Glucagonreceptor knockout mice (Longuet et al., 2008). At the same time,
glucagon receptor knockout mice were more susceptible to
developing a hepatic steatosis. The mentioned genes are well-
known target genes of Foxa2, and reactivation of Foxa2 in the
liver can improve hepatic steatosis in ob/ob or db/db mice, as
shown in this study and before (Wolfrum et al., 2004). The role
of glucagon in the regulation of hepatic ketogenesis was also
investigated in several studies. It was shown that suppression
of glucagon secretion by somatostatin prevented the develop-
ment of ketoacidosis in type 1 diabetic patients (Gerich et al.,
1975). In isolated hepatocytes, increases in the rate of ketogen-
esis and b-oxidation could be observed after glucagon stimula-
tion, whereas insulin had the opposite effect (Pe´gorier et al.,
1989). These results could also be reproduced in primary human
hepatocytes (Vons et al., 1991) and match the consequences of
Foxa2 activity in the liver, which has been shown to be also
a driver of the transcriptional program of ketogenesis (Wolfrum
et al., 2004). Another recent study revealed that histone H4 acet-
ylation and p300 occupancy at promoters of CPT1a and
HMGCS2, both also Foxa2 target genes, is increased during
fasting (Sengupta et al., 2010). As shown in our study, p300
physically interacts with Foxa2. Thus, PPARa and Foxa2, which
have additive transcriptional activity at the same promoter (Wolf-
rum and Stoffel, 2006), might confer the increased transcrip-
tional activity through p300. Montminy and colleagues showed
that salt-inducible kinase 2 (SIK2) is able to phosphorylate
p300 at Ser89 (Liu et al., 2008), a phosphorylation that has444 Cell Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc.been reported to inhibit p300 transcriptional activity (Yuan
and Gambee, 2000). Upon insulin stimulation p300 Ser89 phos-
phorylation was increased, whereas glucagon decreased it.
We could verify the effect of glucagon stimulation on p300
Ser89 phosphorylation, which also resulted in increased Foxa2
Lys259 acetylation. Based on these results, we propose a model
in which Foxa2 is inactivated by insulin during fed states and (re-)
activated by glucagon upon fasting (Figure 7). Finally, glucagon
has been implicated in the regulation of energy expenditure
and food intake. Earlier studies have shown that oxygen
consumption in rats was increased after glucagon infusion
(Davidson et al., 1957), and in human studies it could be shown
that a pharmacological dose of glucagon increased resting
energy expenditure (Nair, 1987). Additional studies revealed
that glucagon decreases food intake due to increased satiation
(Martin and Novin, 1977; Le Sauter and Geary, 1991). Recently
it was suggested that the inhibitory effect of glucagon on food
intake is partially mediated through direct actions in the brain
(Kurose et al., 2009). It will be interesting to see whether acetyla-
tion and activity of Foxa2 in the central nervous system is also
regulated by glucagon. Foxa2 has been shown to be involved
in the regulation of food intake. In particular Foxa2 regulates
the expression of the orexigenic neuropeptides MCH and orexin
in the lateral hypothalamus (Silva et al., 2009).
The metabolic and physiological consequences of Foxa2
Lys259 acetylation were studied in several mouse models,
including lean, obese, and diabetic animals. A Foxa2 mutant
mimicking acetylated Lys259 was transcriptionally active and
nuclear, independent of the nutritional or physiological state of
the mice. As a consequence, hepatic expression of this mutant
was able to improve the metabolic phenotype of ob/ob and
db/db mice. In particular, hyperinsulinemia, hyperglycemia,
and hepatic steatosis were significantly improved, comparable
to levels observed with the constitutively active Foxa2 mutant
T156A. In contrast, the acetylation-deficient Lys259 mutant
was inactive and predominantly cytoplasmic and had no
metabolic beneficial effects when expressed in livers of obese
or diabetic animals. In addition, the Foxa2 double mutant
K259R-T156A was also inactive, suggesting a hierarchical regu-
lation of Foxa2 by PTMs regarding its subcellular localization and
activity and indicating that the effect of Lys259 acetylation is
dominant over Thr156 phosphorylation. Sirt1, one of the HDACs
involved in Foxa2 Lys259 deacetylation is a major regulator of
cellular energy homeostasis (Houtkooper et al., 2012), but its
function in the liver is still controversial. Several studies have as-
sessed the role of Sirt1 in the liver and found that Sirt1 can either
inhibit or enhance hepatic glucose production through interact-
ing with different proteins under different physiological condi-
tions (Rodgers et al., 2005; Banks et al., 2008; Liu et al., 2008;
Erion et al., 2009; Wei et al., 2011), and it has also been reported
that Sirt1 loss accelerates or protects against hepatic steatosis
(Chen et al., 2008; Purushotham et al., 2009). Also, the notion
that Sirt1 activity is increased by caloric restriction (Cohen
et al., 2004) has been challenged (Chen et al., 2008). Our study
revealed that, in addition to Sirt1, other HDACs also deacetylate
Foxa2, and this process might be regulated by the physiological
and metabolic state. It will be important to study the regulatory
network of HDACs and their regulation by signaling pathways
with respect to Foxa2 activity.
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Materials
Human recombinant insulin, glucagon, forskolin, nicotinamide and trichostatin
A were purchased from Sigma-Aldrich. Antibodies for HA, Foxa2, P-IRb,
IRb, HSP90, g-tubulin, p300, GCN5, and lamin B were from Santa Cruz;
GAPDH was from Abcam; and Sirt1 was from Sigma. Ac-Lys, P-Akt, Akt,
P-GSK3a/b, P-S6K, P-Creb, Creb, P-S6rp, S6rp, HDAC3, HDAC5, HDAC7,
and SRC-1 antibodieswere purchased fromCell Signaling. Polyclonal antiace-
tylated Foxa2 (Lys259) was generated by immunizing rabbits with a synthetic
acetylated peptide corresponding to the residues 10 and +10 surrounding
Lys259 of Foxa2. Antibodies were purified by peptide affinity chromatography
(21st Century Biochemicals).
Plasmids
HA-FLAG-tagged Foxa2 wild-type and mutants were in pcDNA3 expression
vectors as previously described (Wolfrum et al., 2003). Lys259 and Lys275
constructs were generated by site-directed mutagenesis, and the sequences
were confirmed by sequencing. The following additional expression vectors
were used: p300 (Addgene plasmid 10718), p300D33 (Addgene plasmid
10719), PCAF (Addgene plasmid 8941), and SRC-1, Tip60, and GCN5 (kindly
provided by Pere Puigserver).
Recombinant Adenoviruses
Adenoviruses were generated using the Rapid Adenovirus Production System
(ViraQuest Inc.). GFPwas coexpressed from an independent promoter in addi-
tion to HA-tagged Foxa2. Ad-GFP, Ad-Foxa2, and Ad-T156A were described
previously (Wolfrum et al., 2004). For in vivo experiments, mice were injected
through the tail vein with 8 3 108 plaque-forming units (pfu) of adenovirus in
200 ml PBS. Empty virus expressing only GFP served as control (Ad-GFP).
Animal Models
All animals studied were 8- to 12-week-old male C57BL/6, ob/ob, or db/db
mice, purchased from Charles River and maintained on a normal chow diet
and a 12 hr light/dark cycle in a pathogen-free animal facility. All animal studies
were approved by the Ethics committee of the Kantonale Veterina¨ramt Zu¨rich.
Cell Lines and Primary Hepatocytes
HepG2 cells were maintained as described before (Howell and Stoffel, 2009).
Hepa1-6 cells were maintained in DMEM (4.5 g/l glucose, 110 mg/l pyruvate,
4 mM L-glutamine, 100 U/ml Pen/Strep) supplemented with 10% fetal bovine
serum (Sigma). Serum starvation was carried out for 16 hr in DMEM without
FBS and Pen/Strep. Primary hepatocytes were isolated as previously
described (Wolfrum et al., 2004) and maintained in DMEM (1 g/l glucose,
110 mg/l pyruvate, 4 mM L-glutamine, 100 U/ml Pen/Strep). All cells were
cultured in a humidified incubator at 37C and 5% CO2.
Nuclear/Cytosolic Extracts
Hepa1-6 cells were grown to 80% confluency and serum-starved for 18 hr,
followed by the indicated treatments (TsA/Nam: 2 hr with 5 mM TsA and
5 mM Nam; insulin: 500 nM human recombinant insulin for 15 min at 37C).
Nuclear and cytoplasmic extracts were prepared as previously described
(Howell and Stoffel, 2009). Briefly, cells were swollen on ice in hypotonic lysis
buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl) containing DTT,
TsA, Nam, and protease inhibitors (Complete mixture, Roche Applied Science)
and permeabilized by the addition of NP40 to 0.6%. After centrifugation at
10,400 3 g for 30 s at 4C, the supernatants (cytoplasmic extracts) were
collected, and nuclear pellets were resuspended in nuclear lysis buffer
(10 mM HEPES [pH 7.9], 100 mM KCl, 3 mMMgCl2, 0.1 mM EDTA) containing
DTT, TsA, Nam, and protease inhibitors. Nuclei were lysed by the gradual
addition of one-tenth volume of 4M (NH4)2SO4 over 30 min. For liver experi-
ments,50mg of liver was dounced in ice-cold hypotonic lysis buffer 10 times
with a tight piston.
Whole-Cell Lysis and Immunoblotting
For whole-cell lysis, cells were washedwith ice-cold PBS and dissolved in lysis
buffer (1% Triton X-100, 50mMTris [pH 7.5], 300mMNaCl, 1mMEGTA, 1mM
EDTA, 0.1% SDS) containing TsA, Nam, protease (Complete mixture, RocheCeApplied Science), and phosphatase inhibitors (Halt Phosphatase Inhibitor
Cocktail, Pierce). Equal amounts of cell lysates were separated on SDS-
PAGE and blotted onto a nitrocellulose membrane (Immobilon). Proteins
were detected by immunoblotting with ECL detection. For liver experiments,
50 mg of liver was processed with a TissueLyser (QIAGEN) directly in
whole-cell lysis buffer.
Immunoprecipitation
HA-tagged Foxa2 were immunoprecipitated from whole-cell lysates using
anti-HA-Agarose (Sigma) or polyclonal anti-Foxa2 antibodies for 1 hr at 4C.
TsA, Nam, protease, and phosphatase inhibitors were added to all buffers.
Proteins were eluted with SDS-loading buffer and separated by SDS-PAGE.
Immunofluorescence Microscopy
Liver pieces were frozen directly in OCT at80C. Sections were cut on a cry-
otome at 8–10 mm thickness, fixed in 4% PFA (in PBS) for 7 min, and frozen
again. Slideswere thawed, washed three times for 5min in PBS, permeabilized
for 10min with 0.3%Triton X-100 in PBS, rinsed with PBS, and blocked for 1 hr
at room temperature in PBS 0.025% Triton X-100, 1% BSA, and 5% goat
serum. Slides were incubated overnight at 4C in PBS 0.025% Triton X-100,
1% BSA, and 5% goat serum with 1:50 HA.11 Clone 16B12 Monoclonal
Antibody, Alexa Fluor Labeled (Covance A594-101L). Slideswere thenwashed
three times for 15 min with 0.025% Triton X-100 in PBS and mounted with
DAPI (H-1200 Reactolab). Images were scanned on a Leica Confocal TCS
SPE at 403.
Oil Red O Staining
Frozen sections (7 mm) from OCT-embedded, snap-frozen liver tissues were
fixed with 5% formalin, washed once in 60% isopropanol, and stained with
0.5% oil red O in propylene glycerol for 1 hr at room temperature. Sections
were washed with isopropanol and mounted.
Gene Expression
RNAwas isolated from 20mg of liver tissue using anRNA extraction kit (Sigma)
and treated with DNase I (Sigma). Five milligrams of total RNA was used for
first-strand cDNA synthesis using SuperScript III RT and hexamer primers
(Invitrogen). PCR products were measured as a function of SYBR Green incor-
poration using LightCycler 480 SYBR Green I Master mix (Roche) and the
Mx3005P Real-Time QPCR Detection System (Stratagene). Values shown
are given in arbitrary units based on a standard curve and normalized to 36B4.
Transfection and RNA Interference
Hepa1-6 cells and primary hepatocytes were transfected using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. For gene-
silencing experiments, cells were transfected with 50 nM siRNA using Lipo-
fectamine RNAiMAX (Invitrogen) following a forward transfection protocol.
Cells were harvested 48 or 72 hr posttransfection. siRNAs were purchased
from Dharmacon (Smart Pools).
Physiological and Metabolic Measurements
Blood glucose wasmeasured using a standard glucometer (Ascensia Contour,
Bayer). Ketone bodies and free fatty acids were measured by a colorimetric
assay system (Wako Chemicals); cholesterol and triglycerides were deter-
mined by a colorimetric assay system (Roche). Plasma insulin levels were
measured with the Sensitive Rat Insulin RIA kit (Linco Research). Liver triglyc-
erides were extracted by the Folch method (Folch et al., 1957) and quantified
by colorimetric assay (Roche). For the insulin tolerance test, mice were intra-
peritoneally injected with 0.54 U/kg or 2 U/kg of human recombinant insulin,
and blood glucose was monitored over 120 min. Area under the curve was
calculated excluding the 15 min time points.
Mitochondrial b-Oxidation and Ketone Body Formation
Mitochondria were isolated from 200 mg of PBS-perfused mouse livers by
differential centrifugation, as previously described (Hoppel et al., 1979).
b-oxidation of [1-14C]palmitic acid or [1-14C]oleic acid by liver mitochondria
in samples normalized to mitochondrial protein was determined as described
(Fre´neaux et al., 1988). CO2 trapped on NaOH moistened filter papers was
determined by measuring 14C radiation in a scintillation counter. Ketonell Metabolism 17, 436–447, March 5, 2013 ª2013 Elsevier Inc. 445
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Regulation of Foxa2 Activity by Glucagonbody formation was assayed in the supernatant of the incubation mixture after
centrifugation at 4,0003 g for 10 min. 14C acid-soluble products of mitochon-
drial b-oxidation were counted from an aliquot of the supernatant.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as described (Nelson
et al., 2006). Details are given in the Supplemental Experimental Procedures.
Mass Spectrometry
MS analyses are described in detail in the Supplemental Experimental
Procedures.
Statistical Analysis
Statistics were determined using the unpaired Student’s t test with Prism
software. Data are calculated as the mean ± SD unless otherwise indicated.
Statistical significance is represented in figures by *, p % 0.05; **, p % 0.01;
***, p% 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2013.01.014.
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